Externe validatie van de Prostaatwijzer binnen een Nederlands klinisch hoogrisicocohort

Marinus J. Hagens; Piter J. Stelwagen; Hans Veerman; Sybren P. Rynja; Martijn Smeenge; Vincent van der Noort; Ton A. Roeleveld; Jolien van Kesteren; Sebastiaan Remmers; Monique J. Roobol; Pim J. van Leeuwen; Henk G. van der Poel

doi:10.1007/s13629-023-00391-4

Externe validatie van de Prostaatwijzer binnen een Nederlands klinisch hoogrisicocohort

Translated title of the contribution: External validation of the Rotterdam Prostate Cancer Risk Calculator within a Dutch high-risk clinical cohort

Marinus J. Hagens^*
, Piter J. Stelwagen
, Hans Veerman
, Sybren P. Rynja
, Martijn Smeenge
, Vincent van der Noort
, Ton A. Roeleveld
, Jolien van Kesteren
, Sebastiaan Remmers
, Monique J. Roobol
, Pim J. van Leeuwen
, Henk G. van der Poel

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Article › Academic › peer-review

17 Downloads (Pure)

Abstract

The positive effect of the Rotterdam Prostate Cancer Risk Calculator (RPCRC)-3/4 and RPCRC-MRI has already been confirmed. Nevertheless, its performance and applicability in clinical practice are still questioned. This study performs an external validation of the RPCRC-3/4 and -MRI within a Dutch clinical high-risk cohort. Men (n = 1,575) subjected to prostate biopsies between 2018 and 2021 due to a clinical suspicion of prostate cancer (PCa) were retrospectively included. PCa and clinically significant PCa (csPCa) were diagnosed in 996/1,575 (63.2%) and 656/1,575 (41.7%) men, respectively. The analysis showed that the RPCRC-3/4 underestimates the risk of csPCa within this Dutch high-risk clinical cohort: even though the RPCRC-3/4 could have prevented 37.3% of all MRIs, 18.3% of csPCa diagnoses would have been consequently missed. Recalibration of this risk calculator and adjustment of its risk thresholds was therefore indicated. The RPCRC-MRI, on the other hand, performed adequately and recalibration was not necessary.

Translated title of the contribution	External validation of the Rotterdam Prostate Cancer Risk Calculator within a Dutch high-risk clinical cohort
Original language	Dutch
Pages (from-to)	98-105
Number of pages	8
Journal	Tijdschrift voor Urologie
Volume	13
Issue number	5
DOIs	https://doi.org/10.1007/s13629-023-00391-4
Publication status	Published - Aug 2023

Bibliographical note

Publisher Copyright:
© 2023, The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s13629-023-00391-4Licence: CC BY

Externe validatie van de Prostaatwijzer binnen een Nederlands klinisch hoogrisicocohortFinal published version, 933 KBLicence: CC BY

Cite this

Hagens, M. J., Stelwagen, P. J., Veerman, H., Rynja, S. P., Smeenge, M., van der Noort, V., Roeleveld, T. A., van Kesteren, J., Remmers, S., Roobol, M. J., van Leeuwen, P. J., & van der Poel, H. G. (2023). Externe validatie van de Prostaatwijzer binnen een Nederlands klinisch hoogrisicocohort. Tijdschrift voor Urologie, 13(5), 98-105. https://doi.org/10.1007/s13629-023-00391-4

@article{e1c5b223fde1497b8deb9e43f0de7883,

title = "Externe validatie van de Prostaatwijzer binnen een Nederlands klinisch hoogrisicocohort",

abstract = "The positive effect of the Rotterdam Prostate Cancer Risk Calculator (RPCRC)-3/4 and RPCRC-MRI has already been confirmed. Nevertheless, its performance and applicability in clinical practice are still questioned. This study performs an external validation of the RPCRC-3/4 and -MRI within a Dutch clinical high-risk cohort. Men (n = 1,575) subjected to prostate biopsies between 2018 and 2021 due to a clinical suspicion of prostate cancer (PCa) were retrospectively included. PCa and clinically significant PCa (csPCa) were diagnosed in 996/1,575 (63.2\%) and 656/1,575 (41.7\%) men, respectively. The analysis showed that the RPCRC-3/4 underestimates the risk of csPCa within this Dutch high-risk clinical cohort: even though the RPCRC-3/4 could have prevented 37.3\% of all MRIs, 18.3\% of csPCa diagnoses would have been consequently missed. Recalibration of this risk calculator and adjustment of its risk thresholds was therefore indicated. The RPCRC-MRI, on the other hand, performed adequately and recalibration was not necessary.",

author = "Hagens, \{Marinus J.\} and Stelwagen, \{Piter J.\} and Hans Veerman and Rynja, \{Sybren P.\} and Martijn Smeenge and \{van der Noort\}, Vincent and Roeleveld, \{Ton A.\} and \{van Kesteren\}, Jolien and Sebastiaan Remmers and Roobol, \{Monique J.\} and \{van Leeuwen\}, \{Pim J.\} and \{van der Poel\}, \{Henk G.\}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = aug,

doi = "10.1007/s13629-023-00391-4",

language = "Dutch",

volume = "13",

pages = "98--105",

journal = "Tijdschrift voor Urologie",

issn = "2211-3037",

publisher = "Springer Science+Business Media",

number = "5",

}

TY - JOUR

T1 - Externe validatie van de Prostaatwijzer binnen een Nederlands klinisch hoogrisicocohort

AU - Hagens, Marinus J.

AU - Stelwagen, Piter J.

AU - Veerman, Hans

AU - Rynja, Sybren P.

AU - Smeenge, Martijn

AU - van der Noort, Vincent

AU - Roeleveld, Ton A.

AU - van Kesteren, Jolien

AU - Remmers, Sebastiaan

AU - Roobol, Monique J.

AU - van Leeuwen, Pim J.

AU - van der Poel, Henk G.

PY - 2023/8

Y1 - 2023/8

N2 - The positive effect of the Rotterdam Prostate Cancer Risk Calculator (RPCRC)-3/4 and RPCRC-MRI has already been confirmed. Nevertheless, its performance and applicability in clinical practice are still questioned. This study performs an external validation of the RPCRC-3/4 and -MRI within a Dutch clinical high-risk cohort. Men (n = 1,575) subjected to prostate biopsies between 2018 and 2021 due to a clinical suspicion of prostate cancer (PCa) were retrospectively included. PCa and clinically significant PCa (csPCa) were diagnosed in 996/1,575 (63.2%) and 656/1,575 (41.7%) men, respectively. The analysis showed that the RPCRC-3/4 underestimates the risk of csPCa within this Dutch high-risk clinical cohort: even though the RPCRC-3/4 could have prevented 37.3% of all MRIs, 18.3% of csPCa diagnoses would have been consequently missed. Recalibration of this risk calculator and adjustment of its risk thresholds was therefore indicated. The RPCRC-MRI, on the other hand, performed adequately and recalibration was not necessary.

AB - The positive effect of the Rotterdam Prostate Cancer Risk Calculator (RPCRC)-3/4 and RPCRC-MRI has already been confirmed. Nevertheless, its performance and applicability in clinical practice are still questioned. This study performs an external validation of the RPCRC-3/4 and -MRI within a Dutch clinical high-risk cohort. Men (n = 1,575) subjected to prostate biopsies between 2018 and 2021 due to a clinical suspicion of prostate cancer (PCa) were retrospectively included. PCa and clinically significant PCa (csPCa) were diagnosed in 996/1,575 (63.2%) and 656/1,575 (41.7%) men, respectively. The analysis showed that the RPCRC-3/4 underestimates the risk of csPCa within this Dutch high-risk clinical cohort: even though the RPCRC-3/4 could have prevented 37.3% of all MRIs, 18.3% of csPCa diagnoses would have been consequently missed. Recalibration of this risk calculator and adjustment of its risk thresholds was therefore indicated. The RPCRC-MRI, on the other hand, performed adequately and recalibration was not necessary.

UR - https://www.scopus.com/pages/publications/85153056576

U2 - 10.1007/s13629-023-00391-4

DO - 10.1007/s13629-023-00391-4

M3 - Article

AN - SCOPUS:85153056576

SN - 2211-3037

VL - 13

SP - 98

EP - 105

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

IS - 5

ER -

Externe validatie van de Prostaatwijzer binnen een Nederlands klinisch hoogrisicocohort

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this